Therapeutic effects of Jiaotai pill on rat insomnia via regulation of GABA signal pathway

Na-na Tang¹,², Chang-wen Wu¹, Ming-qi Chen³, Xue-ai Zeng³, Xiufeng Wang³, Yu Zhang³ and Jun-shan Huang¹,³*

¹Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, 350122, ²Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi, 330004, ³The Sleep Research Center of Fujian Provincial Institute of Traditional Chinese Medicine, Fuzhou, Fujian 350003, China.

*For correspondence: Email; hjjsjtcm@163.com

INTRODUCTION

Insomnia is one of the most common clinical diseases, and is also the most common sleep disorder [1,2]. It is reported that the occurrence of insomnia is often related to psychological depression and anxiety, negative emotions caused by life events or disease [3]. Results of epidemiological studies indicate that the incidence of insomnia in adolescents and the elderly are approximately 11 and 40 %, respectively [3,4]. Thus, research efforts have increasingly focused on the search for insomnia therapy. The anti-insomnia drugs currently in clinical use are mainly western medications, amongst which are benzodiazepine receptor agonists. However these drugs are associated with side-effects, dependence and tolerance over...
time. It has been demonstrated that Chinese traditional medicine system has significant effect on insomnia, and it also has low adverse side effect [5].

Jiaotai pill (JTP) is a traditional Chinese medicinal preparation which contains two Chinese herbal medicines (Coptidis rhizoma and Cinnamomi cortex) [6]. Many studies have shown that JTP has the significant therapeutic effects on insomnia [6-8]. However, the possible mechanism of JTP-induced therapy of insomnia has not been studied clearly so far. The present study was designed to investigate the effects of JTP on insomnia, and to explore the underlying mechanisms.

EXPERIMENTAL

Chemicals and reagents

The reference standards (γ-aminobutyric acid and glutamic acid, p-chlorophenylalanine (PCPA), ortho-phthalaldehyde and sodium pentobarbital were obtained from Sigma-Aldrich (St. Louis, MO, USA). Estazolam was obtained from Kunming Zhenhua Pharmaceutical Co. (Kunming, China). The primary antibodies of glutamate decarboxylase (GAD)-65, GAD-67, γ-aminobutyric acid transaminase (GABA-T), anti-GABA transporter (GAT)-1, anti-GABA transporter (GAT)-3, GABA receptors (GABA-A and GABA-B) were purchased from Abcam Co. (Cambridge, MA, USA). All other chemical reagents used in this study were of analytical grade.

Animals

Male specific pathogen-free (SPF) rats (weighing 180 – 220 g) were purchased from the Laboratory Animal Center of Fujian Medical University (Fuzhou, China). The animals were maintained under controlled conditions with natural lighting, and allowed free access to food and water. All the animal experimental protocols were performed in accordance with “Principles of Laboratory Animal Care” (NIH publication no. 85-23, revised 1985) [9], and were approved by the Animal Care and Use Committee of Fujian University of Traditional Chinese Medicine [no. 2016-04-05].

Animal grouping and treatment

Insomnia animal model was established according to previously reported method with minor modifications [10]. Male rats were administrated PCPA by intraperitoneal injection (350 mg/kg, i.p.) once a day for 2 days. A total 50 male insomnia rats were divided into 5 groups (n = 10), which consisted of model group, positive treated group and 3 JTP treated groups (0.6, 1.2 and 2.4 g/kg). In addition, a group of 10 insomnia-free rats served as normal control. Rats in normal and model groups were treated with normal saline (10 mL/kg). After 14 days of continuous drug/saline treatment, all the rats were injected i.p. with sodium pentobarbital (45 mg/kg). Then, the sleep latency and sleep time were recorded, and the rats were sacrificed by decollation. The hypothalamus of each rat was carefully excised and stored at -80 °C prior to analysis.

Determination of GABA and Glu contents of hypothalamus

The levels of GABA and Glu in the hypothalamus were determined by HPLC method with pre-column derivatization assays [7,11]. In this procedure, 1 mL HClO4 (0.1 mol/L) was added to 0.2 g hypothalamic tissue, and the tissue was then homogenized at 4 °C and centrifuged at 12000 rpm for 20 min at the same temperature. To 40 μL of the supernatant fraction was added 40 μL of orthophthalaldehyde (OPA) solution, and mixed. The resultant solution was kept for few minutes in the dark. The OPA solution was prepared by mixing 10 mg OPA, 1 mL methanol, 9 mL boric acid buffer (pH = 11, 0.04 mol/L) and 40 μL 2-mercaptoethanol. The solution was filtered through a 0.22 μm filter before HPLC analysis. GABA and Glu standards were labeled in the same manner as the hypothalamic tissue samples.

The OPA-labeled hypothalamic tissue samples and standards were analyzed by HPLC (Shimadzu, LC-2010A, Japan) with C18 column (4.6 mm × 250 mm, 5 μm). Solution A was phosphate buffer (25 mmol/L, pH 6.8) with 3 % acetonitrile. Solution B was phosphate buffer (25 mmol/L, pH 6.8) with 50 % acetonitrile. The mobile phase was a mixture of solution A and solution B according to the following gradient: 0 – 15 min, 15 % solution B; 15 – 50 min, 30 % solution. The flow rate and the temperature of the column were set to 1.0 mL/min and 30 °C, respectively. The wavelengths for fluorescence detection and excitation were set at 425 and 338 nm, respectively.

Western blotting assay

The hypothalamic tissues were cut into small sections and treated with lysis buffer containing protease and phosphatase inhibitors. The supernatant was obtained by centrifugation at
12000 rpm for 15 min at 4 °C. Total protein concentration of the supernatant was measured using BCA protein assay reagent (Pierce, Rockford, IL, US). Then, 35 μg proteins were separated by 12 % SDS/PAGE, transferred to polyvinylidene difluoride (PVDF) membrane and probed with various primary antibodies (GAD-65, GAD-67, GABA-T, GAT-1, GAT-3, GABA-A and GABA-B), followed by incubation with the secondary antibodies. The target protein bands were visualized by chemiluminescence detection, and GAPDH was used to normalize the protein loading.

**Statistical analysis**

All data are expressed as mean ± standard deviation (SD) and group comparison was performed by ANOVA (SPSS 16.0). *P < 0.05* was considered statistically significant (* and ** represent significance at 0.05 and 0.01 levels, respectively).

**RESULTS**

**Effect of JTP on latent period and sleeping time**

The effects of JTP on sleep latency and sleep time of rats with insomnia are presented in Figures 1 and Figure 2. The results showed that the latent period of model rat was significantly longer than that of normal rat, whereas the sleeping time was remarkably shorter, indicating that the insomnia model was successfully established. The latent periods of rats in the positive treated group and 3 treated JTP groups (0.6, 1.2 and 2.4 g/kg) were significantly decreased when compared with that of model rats (*P < 0.01*). Furthermore, the sleeping time of JTP treated rats was significantly longer than that of model rats (*P < 0.01*).

**Contents of GABA and Glu in hypothalamus**

The levels of GABA and Glu in hypothalamus of the rats are shown in Figure 3 and Figure 4. GABA content of rat in model group was significantly lower than that of normal rat (*P < 0.01*). However, Glu levels in model rats were significantly increased (*P < 0.01*). More importantly, after treatment with JTP (0.6, 1.2 and 2.4 g/kg), GABA contents were significantly increased (*P < 0.05, **P < 0.01*) whereas Glu levels were significantly decreased, when compared with the model rats (*P < 0.01*).
Effect of Jiaotai pill on expressions of GABA signal-related proteins

As can be seen from Figure 5, expressions of GAD-65, GAD-67, GAT-1, GAT-3, GABA-A and GABA-B were down-regulated in insomnia rats when compared to the normal rats (p < 0.01). However, JTP at dose of 2.4 g/kg significantly up-regulated expressions of GAD-65 (p < 0.01), GAD-67 (p < 0.05), GAT-1 (p < 0.01), GAT-3 (p < 0.01), GABA-A (p < 0.01) and GABA-B (p < 0.01) in hypothalamus of insomnia rats, when compared with untreated insomnia rats. Furthermore, GABA-T was up-regulated in insomnia rats relative to normal rats (p < 0.01), and the JTP (2.4 g/kg) treatment down-regulated GABA-T expression in insomnia rats compared to model rats (p < 0.01).

**DISCUSSION**

GABA and Glu, two major neurotransmitters, exert effects on the excitation/inhibition balance in the central nervous system (CNS) [12]. GABA, an important non-protein amino acid, has inhibitory effects on CNS through blockage of excessive excitement of excitatory neurons [11]. In addition, Glu is recognized as an important excitatory neurotransmitter [13]. Therefore, the contents of GABA and Glu could be used to reflect the degree of insomnia. In the present study, JTP increased the GABA content of hypothalamus of insomnia rats, but decreased the Glu content. This indicates that JTP is a potential source of drug(s) for relieving symptoms of insomnia.

Figure 5: Effect of Jiaotai pill on expressions of GABA signal-related proteins in insomnia rats. 1-3 represented the Normal, Model and JTP (2.4 g/kg), respectively. Data were expressed as mean ± SD (n = 10); *p < 0.05, **p < 0.01, compared with model group.
The GABA signal pathway performs two functions: synthesis and transport of GABA, and synaptic and non-synaptic release of GABA [14]. The synaptic release of GABA is related to certain proteins such as GAD-65, GAD-67 and GABA-T, which are responsible for converting glutamate to the GABA [15,16]. The transport of GABA neurotransmitter is related to GABA transporters such as GAT-1, GAT-1, GAT-1 and GAT-3, which belong to the solute carrier 6 genes family A (SLC6A) of Na+-dependent transporters [17].

GAT regulates the GABA concentration in the brain and is used as new drug for the treatment of treating several CNS diseases [17-19]. In addition, GABA signal pathway is mediated by the two major GABA receptors (GABA-A and GABA-B). GABA-A receptor responds to GABA release by producing excitatory and inhibitory cellular responses. The inhibitory effects of GABA-B on GABA release influences circadian control [14]. In the present study, results of western blotting assay showed that JTP up-regulated the expressions of GAD-65, GAD-67, GAT-1, GAT-3, GABA-A and GABA-B, whereas it down-regulated the expression of GABA-T.

CONCLUSION

The results obtained in the present study demonstrate that JTP exerts sedative effects on PCPA-insomnia in rat. The probable mechanism of action is related to regulation of GABA signal pathway. These findings provide some scientific bases for the clinical use of Jiaotai pill in the treatment of insomnia.

DECLARATIONS

Acknowledgement

This work was supported by National Natural Science Foundation of China (no. 81173149).

Conflict of Interest

No conflict of interest associated with this work.

Contribution of Authors

The authors declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by them.

Open Access

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/raa), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

REFERENCES


